Faculty

Institution

Unit

Venue

Portia Smallbone

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

Portia Smallbone is currently serving as a Breast Surgical Oncology Assistant Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Portia Smallbone

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

medicine hematology bone marrow transplantation cell transplantation stem cell transplantation leukemia clinical transplantation transplantation medicine cell therapy haematopoiesis hematological malignancies organ transplantation graft survival graft rejection myeloid neoplasia pharmacotherapy clinical trials cellular therapy cell replacement therapies pathology clinical research stem cell research surgery applied pharmacology experimental medicine donor age urology translational medicine transplant infectious diseases clinical therapeutics stem-cell therapy clinical pharmacology hla typing malignant blood disorders maintenance therapy post-transplant cyclophosphamide ptcy-based gvhd prophylaxis translational research gastroenterology xenotransplantation digestive diseases gastrointestinal surgery medical virology cancer care medicinal research steroid metabolism transplant surgery acute care surgery bone marrow failure stem cell mobilization mesenchymal stem cells antiviral responses antiviral therapy adult t-cell leukemia-lymphoma metronomic chemotherapy cord blood case series anti-cancer agents antimicrobial chemotherapy translational pharmacology care delivery patient management integrated care multidisciplinary care better tomorrow haploidentical vs unrelated donor hct posttransplant cyclophosphamide prophylaxis myelodysplastic syndrome oral decitabine graft-versus-host disease prophylaxis allograft access personalized selection type trade-offs adult immunocompromised patients adenovirus related disease

Notable Scholarly Works

Notable Federal Grants

Collaborators

Adverse Impact of Mmf in Aml/Mds Patients With High Hct-CI Receiving Matched Allogeneic Stem Cell Transplantation With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

hematologymedicinecell therapystem cellsleukemiabone marrow transplantationptcy-based gvhd prophylaxisimmunologyaml/mds patientscell transplantationstem cell transplantationgraft rejectionadverse impact

A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Mds. Transplantation and Cellular Therapy (2026)

medicinemyeloablative fractionated busulfanoncologymetronomic chemotherapyhigh-risk mdsclinical therapeuticspharmacologyapplied pharmacologyphase 2clinical pharmacologyclinical researchpharmacotherapyclinical trials

Clonal Dynamics of Flt3-Itd Positive Acute Myeloid Leukemia Following Relapse After Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy (2026)

hematologystem cell researchhematological malignancieshaematopoiesiscell biologyleukemiabone marrow transplantationimmunologycell transplantationclonal dynamicsstem cell transplantationpathologymyeloid neoplasia

Evaluate the Safety and Efficacy of Short Versus Long Infusion Schedules of Evomela as Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma.Interpret Bayesian Modeling Results Assessing the Relationship Between Melphalan Exposure (Auc) and Depth of Response or Progression-Free Survival.Identify Potential Pharmacokinetic (Auc) Targets That May Guide Individualized Evomela Dosing Strategies, Particularly for Patients With High-Risk Cytogenetics. Transplantation and Cellular Therapy (2026)

hematologymedicineclinical transplantationhigh-risk cytogeneticsoncologyradiation oncologycancer researchcell therapyhematological malignanciesbone marrow transplantationcell transplantationstem cell transplantationexperimental medicinemelphalan exposure

Lenalidomide Maintenance After Delayed or Salvage Autologous Stem Cell Transplantation. Leukemia & lymphoma/Leukemia and lymphoma (2026)

hematologymedicinecell therapysurgerystem cellsbone marrow transplantationcell transplantationstem cell transplantationlenalidomide maintenance

Mmf Use is Associated With Increased Early Infections in Aml/Mds Patients Undergoing Allogeneic Transplant With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

hematologyorgan transplantationmedicineclinical transplantationgraft survivalhospital infectionsbone marrow transplantationptcy-based gvhd prophylaxisimmunologycell transplantationstem cell transplantationtransplant infectious diseasesgraft rejectionmmf useearly infections

Modeling Donor Age and Type Trade-Offs for Personalized Selection in Allogeneic Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide Prophylaxis. Leukemia (2026)

personalized medicinehematologymedicineclinical transplantationtype trade-offsbone marrow transplantationbiostatisticspersonalized selectioncell transplantationstem cell transplantationcell replacement therapiesdonor agetransplantation medicine

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Aml: A Phase 2 Trial. Transplantation and Cellular Therapy (2026)

hematologymedicinemyeloablative fractionated busulfanhematological malignancieshigh-risk amlmyeloid neoplasialeukemiapharmacologyapplied pharmacologyphase 2clinical pharmacologyexperimental medicineclinical researchpharmacotherapyclinical trials

Myeloablative is Not Always Better: Dismantling the One-Size-Fits-All Approach to Haploidentical Conditioning Intensity. International Journal of Cancer Care and Delivery (2026)

hematologyone-size-fits-all approachalways bettermedicinehaematopoiesisbone marrow transplantationhealth scienceshaploidentical conditioning intensity

Non-Myeloablative/Reduced Intensity is Associated With Comparable Survival Outcomes to Myeloablative Conditioning in Haploidentical Hct. Transplantation and Cellular Therapy (2026)

hematologymedicinecomparable survival outcomesoncologyradiation oncologyhaematopoiesismyeloablative conditioningleukemiabone marrow transplantationcell transplantationstem cell transplantationhaploidentical hctmyeloid neoplasia

1
2
3
4
5
10 / page

Portia Smallbone

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Stem Cell Transplantation

The University of Texas MD Anderson Cancer Center

Portia Smallbone is currently serving as a Breast Surgical Oncology Assistant Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Portia Smallbone

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Adverse Impact of Mmf in Aml/Mds Patients With High Hct-CI Receiving Matched Allogeneic Stem Cell Transplantation With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Mds. Transplantation and Cellular Therapy (2026)

Clonal Dynamics of Flt3-Itd Positive Acute Myeloid Leukemia Following Relapse After Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy (2026)

Lenalidomide Maintenance After Delayed or Salvage Autologous Stem Cell Transplantation. Leukemia & lymphoma/Leukemia and lymphoma (2026)

hematologymedicinecell therapysurgerystem cellsbone marrow transplantationcell transplantationstem cell transplantationlenalidomide maintenance

Mmf Use is Associated With Increased Early Infections in Aml/Mds Patients Undergoing Allogeneic Transplant With Ptcy-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy (2026)

Modeling Donor Age and Type Trade-Offs for Personalized Selection in Allogeneic Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide Prophylaxis. Leukemia (2026)

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk Aml: A Phase 2 Trial. Transplantation and Cellular Therapy (2026)

Myeloablative is Not Always Better: Dismantling the One-Size-Fits-All Approach to Haploidentical Conditioning Intensity. International Journal of Cancer Care and Delivery (2026)

hematologyone-size-fits-all approachalways bettermedicinehaematopoiesisbone marrow transplantationhealth scienceshaploidentical conditioning intensity

Non-Myeloablative/Reduced Intensity is Associated With Comparable Survival Outcomes to Myeloablative Conditioning in Haploidentical Hct. Transplantation and Cellular Therapy (2026)

1
2
3
4
5
10 / page